H. Magnussen (Grosshansdorf, Germany), K. F. Rabe (Leiden, The Netherlands)
Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD
D. A. Mahler, P. Darken, C. P. Brown, K. Knobil (Lebanon, Raleigh, United States Of America)
|  |
Cardiovascular evaluation of tiotropium during constant-work rate exercise in COPD
D. E. O'Donnell, H. Magnussen, F. Gerken, S. Kesten, T. Fluege (Kingston, Canada; Grosshansdorf, Ingelheim, Germany)
| |
Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers: a randomised, placebo controlled, cross-over study
H. J. van der Woude, J. Zaagsma, D. S. Postma, T. H. Winter, M. van Hulst, R. Aalbers (Groningen, The Netherlands)
| |
REVERDIL study: validity of salbutamol in determining COPD reversibility prior to formoterol treatment
M. Mathieu, L. G. Vincent, B. Isabelle (Bordeaux, Rueil-Malmaison, France)
| |
Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs
C. G. Löfdahl, E. Andreasson, K. Svensson, A. Ericsson (Lund, Sweden)
| |
Improvements in FEV1 and symptoms in poorly-reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination
D. Horstman, P. Darken, S. Davis, B. Lee (Raleigh, United States Of America)
| |
Budesonide/formoterol in a single inhaler sustains lung-function improvements in COPD
P. M. A. Calverley, N. C. Thomson, H. Olsson (Liverpool, Glasgow, United Kingdom; Lund, Sweden)
| |
Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD
P. M. A. Calverley, Z. Cseke, S. Peterson (Liverpool, United Kingdom; Szombathely, Hungary; Lund, Sweden)
| |
Salmeterol 50mcg bid significantly improves health status in COPD patients
R. Stockley, S. Sondhi, P. Whitehead, M. Williams (Birmingham, Middlesex, United Kingdom)
| |
Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life
M. Spencer, P. Wire, B. Lee, C. N. Chang, P. Darken, D. Horstman (Greenford, United Kingdom; Raleigh, United States Of America)
| |
COPD: patterns of diagnosis and management
D. B. Coultas, B. Brockman (Jacksonville, United States Of America)
| |
Bronchoalveolar lavage in COPD: fluid recovery correlates with diffusing capacity for carbon monoxide
M. J. Löfdahl, L. Nathell, A. G. Eklund, M. C. Sköld (Stockholm, Are, Sweden)
| |
The lung deposition of tiotropium in COPD patients is comparable to that in healthy subjects and independent of the stage of COPD disease
S. Häußermann, S. Roeder, D. Türck, G. Wallenstein, K. Sommerer, G. Scheuch (Gauting, Biberach, Germany)
| |
Flow-volume responsiveness to bronchodilators in COPD
L. Forkert, D. O'Donnell (Kingston, Canada)
| |
Effects of N-acetylcystein on proteinas-inhibitory system in smokers with chronic obstructive bronchitis (COB)
O. B. Pavlenko, L. I. Konopkina (Dniepropetrovsk, Ukraine)
| |
Do different combinations of bronchodilator therapies have different effects on health status in patients with COPD?
F. Yildiz, I. Basyigit, E. Yildirim, H. Boyaci, A. Ilgazli (Kocaeli, Turkey)
| |
Efficacy of ipratropium bromide/ fenoterol hydrobromide HFA and CFC propellant inhalers in patients with COPD
I. A. Stitsenko, T. I. Leisenberg (St Petersburg, Russia)
| |
Efficacy and cardiovascular safety of long-term bronchodilator therapy with theophylline in patients with chronic obstructive bronchitis (COB)
T. S. Onyshchenko (Dnipropetrovsk, Ukraine)
| |
Efficacy and effectiveness in long-term treatment with different ”new[dcdquote] drug's associations in cold patients
E. Corvaja, F. Andò, G. Girbino, E. Corvaja (Messina, Italy)
| |